Betheball
Agreed. The company said:
Answer: Yes, the Company is sufficiently funded to continue its operations and meet its
business objectives. The Company will continue to maintain eligibility for nondilutive
funding through the R&D Tax Incentive scheme, as well as evaluate its capital
requirements and options.
As it got $8.9 million R&D rebate in 2023 on a smaller spend it is likely to get a much bigger R&D cash payment for 2024.... and there are still a few options to be exercised at only $0.154.
If a distribution agreement is signed in the next few months that will add to the coffers! but is it desperately needed???... likely not.
Those who have been selling recently based on a possible CR will buy back soon............... at well over what they sold for !!
DXB Chart, page-1229
-
- There are more pages in this discussion • 140 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.040(9.76%) |
Mkt cap ! $247.7M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 45.5¢ | 41.5¢ | $820.5K | 1.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34678 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 80601 | 3 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |